Objectives: The aim of this study was to investigate the efficacy and safety of a new
paclitaxel-coated balloon catheter in the treatment of stenotic or occluded femoropopliteal …

Background Atherosclerotic peripheral arterial disease (PAD) can lead to disabling ischemia
and limb loss. Treatment modalities have included risk factor optimization through life‐style …

Objective Several randomized controlled trials (RCTs) have shown the superiority of some of
these technologies over balloon angioplasty, but direct comparisons between these …

Purpose: To provide a qualitative analysis and quantitative synthesis of randomized
controlled trials (RCTs) investigating paclitaxel-coated balloons (PCBs) in the …

Background Clinical outcomes reported after treatment of infrapopliteal lesions with drug‐
eluting stents (DESs) have been more favorable compared with percutaneous transluminal …

Purpose: To assess the association of patient, lesion, and procedure variables, including
calcification, with late lumen loss (LLL) after use of drug-eluting balloon (DEB) therapy in …

Objective The aim was to review and analyse the literature on clinical outcomes of drug
coated balloon (DCB) vs. standard percutaneous transluminal angioplasty (PTA) for the …

Objective To evaluate 1 to 36 month follow-up outcomes of different endovascular treatment
strategies in above-the-knee (ATK) arterial segments in patients with intermittent …

The advent of drug-coated balloons (DCBs) provides a novel means to locally deliver
paclitaxel into the arterial wall without the need of a chronically implanted delivery system …

More than 200 million people worldwide have peripheral artery disease (PAD) or its most
severe manifestation, critical limb ischemia (CLI). While endovascular treatment has become …